絞り込み

16636

広告

Baseline Triglyceride Level Affected the Efficacy of Vildagliptin in Treating Type 2 Diabetes: A Post Hoc Analysis of the VISION Study.

著者 Zhou L , Cai X , Luo Y , Zhang F , Ji L
J Diabetes Res.2019 ; 2019():9347132.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (102view , 0users)

Full Text Sources

Identifying factors that may impact vildagliptin's efficacy could contribute to individualized treatment for patients with type 2 diabetes. In the current study, we aimed to assess the correlation between patient baseline triglyceride (TG) and efficacy of vildagliptin in Chinese patients with type 2 diabetes in a post hoc analysis of the VISION study. TG-based subgroup analysis was performed to evaluate baseline TG's impact on the decrease of glycated hemoglobin (HbA) in patients receiving vildagliptin plus low-dose metformin (VLDM) vs. high-dose metformin (HDM). Additionally, multivariate linear regression was performed to assess the association between baseline TG and HbA reduction at weeks 12 and 24 for patients receiving VLDM vs. HDM. For patients receiving VLDM, baseline TG ≤ 2.03 mmol/L was associated with significantly greater HbA reduction vs. TG > 2.03 mmol/L at week 12, but not at week 24. Additionally, multivariate linear regression analysis revealed a significant independent association and an association short of statistical significance between patient baseline TG and the HbA-reducing efficacy of VLDM at weeks 12 ( < 0.001) and 24 ( = 0.082), respectively, while such association was absent for HDM. Collectively, baseline TG was an independent predictive factor for the efficacy of a dipeptidyl peptidase-IV in treating type 2 diabetes during its initial use.
PMID: 31485457 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード